Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
Pretreatment fasting glucose could block breast cancer progression

Pretreatment fasting glucose could block breast cancer progression

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

AVEO, Boehringer Ingelheim enter development and manufacturing agreement for ficlatuzumab

Scientists identify novel gene mutation that causes glioblastoma

Scientists identify novel gene mutation that causes glioblastoma

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

Biothera completes enrollment in Imprime PGG Phase II combination study on NSCLC

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

CU Cancer Center test identifies key biomarkers in advanced lung cancer

CU Cancer Center test identifies key biomarkers in advanced lung cancer

Clinical study: Higher radiation dose does not improve overall survival for NSCLC

Clinical study: Higher radiation dose does not improve overall survival for NSCLC

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Synta announces results of ganetespib, docetaxel Phase 1 combination study on solid tumors

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Oncothyreon commences enrollment in PX-866 Phase 2 trial for metastatic castration-resistant prostate cancer

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Stage III lung cancer patients can benefit from concurrent chemo and radiation therapy

Scientists discover backup circuits in cetuximab-resistant cancer cells

Scientists discover backup circuits in cetuximab-resistant cancer cells

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Merck decides not to advance IMO-2055 development for squamous cell carcinoma of the head and neck

Merck Serono announces recipients of second Grant for Fertility Innovation

Merck Serono announces recipients of second Grant for Fertility Innovation

Study finds link between genetic variation and cetuximab rectal cancer therapy

Study finds link between genetic variation and cetuximab rectal cancer therapy

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

Patients with high EGFR expression more likely to benefit from cetuximab plus chemotherapy

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Patient enrollment complete in cilengitide Phase III study against glioblastoma

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011

Symphogen's Sym004 Phase 1 trial data on advanced solid tumors presented at ASCO 2011